The impact of intermittent ceralasertib treatment in combination with anti-PD-L1 was studied in several subcutaneous (s.c.)and orthotopic syngeneic tumor models: CT26, MC38, 4T1, and A20. This evidence concerns the gene CD274 and neoplasm.